3 transcripts
CUE
Earnings call transcript
NASDAQ
2024 Q2
19 Aug 24
to maximize efficacy while preserving patient safety. As Dan indicated previously and as summarized on Slide 3, we have now clinically validated Immuno
CUE
Earnings call transcript
NASDAQ
2023 Q4
8 Apr 24
of the immune system. Most importantly, this approach allows us to maximize efficacy while preserving patient safety.
Slide 6 provides an introduction to our
CUE
Earnings call transcript
NASDAQ
2023 Q2
9 Aug 23
and optimized to provide protective immunity while preserving the safety of the host. Using these underlying principles of selectivity, we have
- Prev
- 1
- Next